Eli Lilly reported a robust first quarter, significantly surpassing analyst expectations and subsequently raising its full-year guidance, leading to a notable surge in its stock price.
Q1 Financial Performance Highlights
Eli Lilly's financial results for the three months ended in March demonstrated strong growth across key metrics:
- Revenue: Jumped 56% year-over-year to reach $19.8 billion, beating the LSEG consensus estimate of $17.6 billion.
- Adjusted EPS: Totaled $8.55, more than doubling from the previous year and exceeding the consensus of $6.66.
These strong results caused the stock to surge approximately 10% on the day, despite having been down 21% year-to-date and significantly below its late November high.
Growth Drivers: GLP-1 Dominance
Despite headwinds such as weaker realized drug prices in the U.S. and competition from Novo Nordisk, the company's performance was heavily bolstered by its GLP-1 franchise:
- Volume vs. Price: In Q1, U.S. pricing fell by 7%, but volumes for injectable GLP-1s (Zepbound and Mounjaro) jumped 49%. This dynamic was even more pronounced globally, where pricing dropped 13% but volumes rose by 65%.
- International Strength: Mounjaro's international marketing for both obesity and type 2 diabetes was cited as a standout driver of global volume gains.
Full-Year Guidance and Pipeline Strength
Beyond the quarterly beat, Lilly raised its full-year guidance for revenue, operating profitability, and earnings per share, signaling continued confidence.
- Revised 2026 Guidance: Revenue is now projected to be in the range of $82 billion to $85 billion (up from $80B–$83B previously). Operating profitability is expected between 47% and 48.5%.
- Pipeline Potential: The company's pipeline remains strong, notably with retatrutide, which trials suggest may offer greater weight loss efficacy for type 2 diabetes patients compared to current market offerings.
Foundayo Launch and Market Dynamics
Attention also focused on the launch of the obesity pill, Foundayo (orforglipron), which received FDA approval. CEO David Ricks addressed initial concerns regarding its market uptake:
- Brand Building: Ricks noted that Foundayo is building its brand from scratch, unlike competitors who benefit from established names. He stated that demand is currently coming organically, with over 20,000 prescriptions recorded.
- Market Expansion: A key statistic highlighted was that about 80% of Foundayo prescriptions were for individuals not previously using a GLP-1, suggesting the pill could expand the total addressable market rather than cannibalizing existing injectable sales.
Key Monitoring Points
Investors should monitor the progress of Medicare coverage for obesity drugs, as the pilot program's start has faced delays. The company anticipates benefits from an extended bridge program through the end of 2027.
